article thumbnail

Novartis halts recruitment of Kisqali trials as it adjusts production methods

Fierce Pharma

In response to recent FDA guidelines which limit the nitrosamine content of drugs, Novartis has paused the enrollment of early breast cancer (eBC) patients in clinical trials of its blockbuster Kis | In response to recent FDA guidelines which limit the nitrosamine content of drugs, Novartis has paused the enrollment of early breast cancer (eBC) patients (..)

article thumbnail

Biotechs face upward battle with recruiting patients on obesity trials

Pharmaceutical Technology

As the obesity space becomes more congested, clinical trial recruitment has become a larger issue for small biotechs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Rethinking trial engagement and recruitment starts with patient perspectives: patient survey insights

pharmaphorum

Recruitment for much-needed COVID-19 vaccine and treatment trials accelerated. and the EU in order to examine the perception of clinical research one year into the pandemic and attitudes toward trial participation, including the reasons patients enrol in clinical trials. Leveraging patient perspectives. Interest by demographics.

article thumbnail

Is patient recruitment out of control?

Pharmaceutical Technology

Every year, the patient recruitment landscape is getting larger and more multi-faceted.

article thumbnail

Running Decentralized Trials at Scale: Planning for Success

The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. There’s been a rapid shift towards decentralization in clinical trials & it’s clear why.

article thumbnail

Setting up trials in APAC and Middle East can boost patient recruitment

Pharmaceutical Technology

Setting up trial sites in countries with unmet clinical needs can lead to higher patient recruitment, compared to established trial hubs.

article thumbnail

Invizius’ ‘angry blood’ research recruits 300th patient

PharmaTimes

525-patient trial intends to assess ‘complement activation’ during HD in patients with end stage renal failure - News - PharmaTimes